A rebuttal: Counseling pregnant women with factor V Leiden homozygosity: use absolute instead of relative risks.
Middeldorp
Saskia
S
van der Meer
Jan
J
Hamulyák
Karly
K
Büller
Harry R
HR
D020016:Activated Protein C Resistance / Q000453:epidemiology*; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D003376:Counseling; D005165:Factor V / Q000235:genetics*; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000453:epidemiology*; D011295:Prenatal Care; D011644:Puerperal Disorders / Q000453:epidemiology / Q000209:etiology; D012306:Risk; D019851:Thrombophilia / Q000453:epidemiology*; D020246:Venous Thrombosis / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control
D000925:Anticoagulants; C095381:factor V Leiden; D005165:Factor V; D006493:Heparin